Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Mol Cancer Ther. 2013 Nov 12;12(12):2917–2928. doi: 10.1158/1535-7163.MCT-13-0572

Figure 3. Levels of estrogen modulate the sensitivity of PTEN-null endometrial tumors to PARP inhibition in vivo.

Figure 3

(A) Schema for generation and treatment of tumors. (B) With estrogen supplementation tumors were resistant to PARP inhibition based on histology and tumor weight. Estrogen deprivation sensitized tumors to PARP inhibition demonstrated by reduction in graft size and resolution of tumor tissue.